- Home
- Companies
- canada ontario
- vascular endothelial growth factor c vegf c and vegf d is not equivalent to vegf
Refine by
Vascular Endothelial Growth Factor C Vegf C And Vegf D Is Not Equivalent To Vegf Suppliers Near Canada Ontario
4 companies found
based inTucson, ARIZONA (USA)
Salutaris Medical Devices (SMD) is a clinical-stage medical device company specializing in the treatment of ophthalmic diseases with a precision beta radiotherapy delivery platform. Our globally-patented, 510k-cleared device has the potential to ...
SalutarisMD [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV. The BetaCurve™ curves ...
based inValencia, SPAIN
Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve ...
based inWayne, PENNSYLVANIA (USA)
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our ...
About the EXACT Trial for Refractory Angina Patients. The EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ...